Orgenesis Inc. (OTCQX: ORGS), a global biotech company has recently shared its business update for the third quarter ending September 30, 2024. The company is focused on enhancing access to cell and gene therapies (CGT) through a decentralized production model, which aims to improve efficiency, reduce costs, and ultimately expand patient access to innovative treatments.
Vered Caplan, CEO of Orgenesis, emphasized the company’s commitment to redefining how CGTs are delivered. “Our decentralized approach is designed to expedite capacity setup and enhance production efficiency,” she stated. This model not only aims to lower treatment costs but also facilitates a quicker response to patient needs by allowing hospitals and research centers to build their capabilities for providing CGT products swiftly and cost-effectively.
The company is actively expanding its clinical initiatives and strengthening partnerships globally. This strategy is geared towards creating scalable pathways for advanced therapies, ensuring that patients worldwide can benefit from these innovations.
A highlight from Orgenesis’ recent developments is the real-world study of its CD19 CAR-T therapy, ORG-101. The therapy has shown impressive results, achieving an 82% complete response rate in adults and a 93% complete response rate in pediatric patients suffering from CD19+ Acute Lymphoblastic Leukemia. Notably, ORG-101 also demonstrated a lower incidence of severe Cytokine Release Syndrome compared to traditional CAR-T therapies, 2% in adults and 6% in pediatric patients.
These clinical outcomes not only validate the efficacy of ORG-101 but also reinforce Orgenesis’ decentralized production model as a viable solution for making CAR-T therapies more accessible and affordable on a global scale.
In an exciting development, Orgenesis announced the initiation of a Phase 1/2 multicenter clinical study for ORG-101 at two hospitals in Greece: the University General Hospital of Patras and “George Papanikolaou” General Hospital of Thessaloniki. This initiative is supported by a grant from ‘Enterprise Greece’, with plans to extend the study to additional hospitals within Orgenesis’ partnership network.
Orgenesis is also forging strategic partnerships to enhance its offerings in the healthcare sector. A notable collaboration with Harley Street Healthcare Group (HSHG) aims to leverage Orgenesis’ expertise in CGTs for applications in wellness and longevity. By integrating their innovations with HSHG’s established healthcare network, Orgenesis plans to introduce a suite of services targeting key markets such as the UK, UAE, and Canada.
This partnership exemplifies Orgenesis’ strategy to drive impactful healthcare innovations that improve quality of life across diverse regions. The combination of advanced therapies with established healthcare networks positions the company favorably within the evolving landscape of health services.
Orgenesis continues to make significant strides in making cell and gene therapies more accessible through its innovative decentralized model. With promising clinical results and strategic partnerships underway, the company is positioned to impact patient care positively while pursuing sustainable growth within the biotech industry.
